GlassScriptPhysician profile
Hazem Ubaissi
NPI 1285785907
$2,030.54
in general payments reported to CMS, 2019-2025
26 companies · $352 in 2025
The $352 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $963 · 2020: $461 · 2021: $40.47 · 2022: $45.10 · 2024: $170 · 2025: $352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $521.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $349.49 | 2024-2025 | Inspire |
| Pulmonx Corporation | $275.42 | 2020-2025 | Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
| Astrazeneca Pharmaceuticals LP | $198.49 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $187.07 | 2019-2021 | |
| Glaxosmithkline, LLC. | $175.94 | 2019-2020 | |
| Mylan Specialty L.P. | $96.34 | 2019-2020 | |
| Harmony Biosciences LLC | $90.81 | 2020-2022 | |
| Mallinckrodt Enterprises LLC | $88.84 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $74.43 | 2019 | |
| Sunovion Pharmaceuticals INC. | $53.47 | 2019 | |
| Insmed, INC. | $47.28 | 2019-2020 | |
| Genzyme Corporation | $47.05 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.60 | 2020 | |
| Portola Pharmaceuticals, LLC | $45.28 | 2019 | |
| United Therapeutics Corporation | $40.79 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $32.67 | 2019 | |
| Philips North America LLC | $31.40 | 2019-2020 | |
| Cumberland Pharmaceuticals, INC. | $22.18 | 2019 | |
| 3b Medical, INC. | $21.68 | 2025 | Luna |
| Jazz Pharmaceuticals INC. | $20.59 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.99 | 2019 | |
| Nabriva Therapeutics, Plc | $16.25 | 2020 | |
| Pfizer INC. | $14.23 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.84 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hazem Ubaissi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.